EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring European Consensus About the Remaining Treatment Challenges and Subsequent Opportunities to Improve the Management of Invasive Fungal Infection (IFI) in the Intensive Care Unit

Europäischer Konsens zu verbleibenden Behandlungsproblemen und Möglichkeiten zur Verbesserung des Managements invasiver Pilzinfektionen (IFI) auf der Intensivstation

Martin Hoenigl, David A Enoch, Dominic Wichmann, Duncan Wyncoll, Andrea Cortegiani

Mycopathologia · 2024-06 · 189 (3)

DOI: 10.1007/s11046-024-00852-3 ↗

Auf einen Blick

Eine Delphi-Umfrage unter Fachpersonen aus 5 Ländern zeigte breite Zustimmung zu vielen Aussagen zur Diagnostik und Therapie von IFI auf Intensivstationen. 29/44 Aussagen erreichten 90 % Zustimmung.

Fragestellung

Welche aktuellen Herausforderungen und Verbesserungsmöglichkeiten werden beim Management invasiver Pilzinfektionen auf Intensivstationen in Europa gesehen?

Methode

Modifizierte Delphi-Umfrage mit 44 Likert-Aussagen in 6 Bereichen; Online-Befragung von Intensiv-, Infektions-, Mikrobiologie- und Apothekenfachpersonen aus dem UK, Deutschland, Spanien, Frankreich und Italien.

Ergebnisse

335 Antworten. 29/44 Aussagen (66 %) erreichten sehr hohe Zustimmung (90 %), 11/44 (25 %) hohe Zustimmung (75 % bis <90 %), 4/44 (9 %) verfehlten den Konsens (<75 %).

Einschränkungen

Keine Angabe zur Repräsentativität; Convenience Sampling; Ergebnisse beruhen auf Expertenkonsens.

Schlussfolgerung der Autor:innen

Die Autor:innen heben die Bedeutung lokaler IFI-Inzidenz und Azolresistenz hervor. Bei hoher klinischer Wahrscheinlichkeit soll die Therapie sofort begonnen werden; Beta-D-Glucan soll in allen ICU-Zentren verfügbar sein.

Kernaussagen

  • 29/44 Aussagen erreichten 90 % Zustimmung
  • 335 Antworten aus 5 Ländern
  • Beta-D-Glucan innerhalb von 48 h zur Beendigung empirischer Therapie

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Mycopathologia, online erschienen am 05.05.2024. Verfasst von Martin Hoenigl und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria. hoeniglmartin@gmail.com. Hauptthemen laut MEDLINE: Antifungal Agents, Intensive Care Units, Invasive Fungal Infections. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences Europe Ltd, Medical University of Graz.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The global prevalence of invasive fungal infections (IFI) is increasing, particularly within Intensive Care Units (ICU), where Candida spp. and Aspergillus spp. represent the most important pathogens. Diagnosis and management of IFIs becomes progressively challenging, with increasing antifungal resistance and the emergence of rare fungal species. Through a consensus survey focused on assessing current views on how IFI should be managed, the aim of this project was to identify challenges around diagnosing and managing IFIs in the ICU. The current status in different countries and perceived challenges to date amongst a multidisciplinary cohort of healthcare professionals involved in the care of IFI in the ICU was assessed.

Methods

Using a modified Delphi approach, an expert panel developed 44 Likert-scale statements across 6 key domains concerning patient screening and minimal standards for diagnosis of IFIs in ICU; initiation and termination of antifungal treatments and how to minimise their side effects and insights for future research on this topic. These were used to develop an online survey which was distributed on a convenience sampling basis utilising the subscriber list held by an independent provider (M3 Global). This survey was distributed to intensivists, infectious disease specialists, microbiologists and antimicrobial/ICU pharmacists within the UK, Germany, Spain, France and Italy. The threshold for consensus was set at 75%.

Results

A total of 335 responses were received during the five-month collection period. From these, 29/44 (66%) statements attained very high agreement (90%), 11/44 (25%) high agreement (< 90% and ≥ 75%), and 4/44 (9%) did not meet threshold for consensus (< 75%).

Conclusion

The results outline the need for physicians to be aware of the local incidence of IFI and the associated rate of azole resistance in their ICUs. Where high clinical suspicion exists, treatment should start immediately and prior to receiving the results from any diagnostic test. Beta-D-glucan testing should be available to all ICU centres, with results available within 48 h to inform the cessation of empirical antifungal therapy. These consensus statements and proposed measures may guide future areas for further research to optimise the management of IFIs in the ICU.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsIntensive Care UnitsInvasive Fungal InfectionsHumansDisease ManagementEuropeSurveys and Questionnaires

Stichwörter der Autor:innen

AspergillosisCandidaemiaDelphi studyIntensive care unitsInvasive fungal infections

Substanzen

Antifungal Agents

Autor:innen und Institutionen

  • Division of Infectious Diseases, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria. hoeniglmartin@gmail.com.
  • BioTechMed-Graz, Graz, Austria. hoeniglmartin@gmail.com.
  • ECMM Excellence Center for Medical Mycology, Translational Medical Mycology Research Unit, Medical University of Graz, Graz, Austria. hoeniglmartin@gmail.com.
  • Clinical Microbiology & Public Health Laboratory, UK Health Security Agency, Cambridge University Hospital NHS Foundation Trust, Addenbrookes Hospital, Cambridge, UK.
  • Department of Intensive Care Medicine, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Intensive Care, Guy's and St Thomas' Hospital, London, UK.

Förderung

  • Gilead Sciences Europe Ltd
  • Medical University of Graz

Zitieren

APA

Hoenigl, M., Enoch, D. A., Wichmann, D., Wyncoll, D., & Cortegiani, A. (2024). Exploring European Consensus About the Remaining Treatment Challenges and Subsequent Opportunities to Improve the Management of Invasive Fungal Infection (IFI) in the Intensive Care Unit. Mycopathologia, 189(3). https://doi.org/10.1007/s11046-024-00852-3

Vancouver

Hoenigl M, Enoch DA, Wichmann D, Wyncoll D, Cortegiani A. Exploring European Consensus About the Remaining Treatment Challenges and Subsequent Opportunities to Improve the Management of Invasive Fungal Infection (IFI) in the Intensive Care Unit. Mycopathologia. 2024;189(3). doi:10.1007/s11046-024-00852-3

BibTeX
@article{Hoenigl2024,
  author = {Hoenigl, Martin and Enoch, David A and Wichmann, Dominic and Wyncoll, Duncan and Cortegiani, Andrea},
  title = {Exploring European Consensus About the Remaining Treatment Challenges and Subsequent Opportunities to Improve the Management of Invasive Fungal Infection (IFI) in the Intensive Care Unit},
  journal = {Mycopathologia},
  year = {2024},
  volume = {189},
  number = {3},
  doi = {10.1007/s11046-024-00852-3}
}
Kostenlos starten →